A renaissance in marine pharmacology: from preclinical curiosity to clinical reality.
Marine pharmacology, the pharmacology of marine natural products, has been for some time more associated with marine natural products chemistry rather than mainstay pharmacology. However, in recent years a renaissance has occurred in this area of research, and has seen the US Food & Drug Administration (FDA) approval in 2004 of Prialt (ziconotide, omega-conotoxin MVIIA) the synthetic equivalent of a conopeptide found in marine snails, used for the management of severe chronic pain. Furthermore Yondelis) (trabectedin, ET-743) an antitumor agent scovered in a marine colonial tunicate, and now produced synthetically, receiving Orphan Drug designation from the European Commission (EC) and FDA for soft tissue sarcomas and ovarian cancer and its registration in 2007 in the EU for the treatment of soft tissue sarcoma. The approval/marketing of so few marine natural products has come after many years of research primarily by the academic community and the sporadic involvement of major pharmaceutical companies. This commentary, through the opinions provided by several leaders in the marine natural products field, will examine the potential reasons and perceptions from both the academic and pharmaceutical communities regarding the development of marine natural products as viable therapeutic entities.
Glaser
Keith B
KB
Cancer Research R47J-AP9, Abbott Laboratories, Abbott Park, IL 60064-6121, USA. keith.glaser@abbott.com
Mayer
Alejandro M S
AM
D001688:Biological Products / Q000302:isolation & purification* / Q000494:pharmacology; D017277:Drug Approval / Q000331:legislation & jurisprudence; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008386:Marine Biology; D014481:United States; D014486:United States Food and Drug Administration
D001688:Biological Products